This study involves people with cardiovascular disease who have a buildup of fatty deposits called plaque in the arteries of the heart and high levels of a substance in the blood called lipoprotein(a). The treatment being tested is olpasiran, which is also known by the code name AMG 890, or placebo. Olpasiran is a type of medicine designed to lower lipoprotein(a) levels in the blood. High levels of lipoprotein(a) are linked to an increased risk of heart problems because they can contribute to the buildup of plaque in the arteries.
The purpose of this study is to find out if olpasiran can reduce the amount of a specific type of plaque in the heart arteries called non-calcified plaque, which is softer plaque that has not yet hardened with calcium deposits. The study will also look at whether the treatment is safe and well tolerated by participants. The amount of plaque will be measured using a special imaging test called coronary computed tomography angiography, which creates detailed pictures of the heart arteries.
During the study, participants will receive either olpasiran or placebo through an injection under the skin using a pre-filled syringe. The study will last for approximately 72 weeks, during which time imaging scans will be performed to compare the amount of plaque in the arteries at the beginning and end of the treatment period. The study will also measure changes in other types of plaque, including low attenuation plaque, which is a type of softer plaque, total plaque volume, and calcified plaque, which is hardened plaque containing calcium deposits.
Denmark 
France 
Germany 
Italy 
Spain 
The Netherlands 
